GlassScriptPhysician profile
Kaili Gehring
NPI 1164774212
$3,390.37
in general payments reported to CMS, 2019-2025
22 companies · $1,147 in 2025
The $1,147 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $404 · 2022: $306 · 2023: $465 · 2024: $1,069 · 2025: $1,147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,681.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,680.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $624.43 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $528.70 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $400.17 | 2023-2025 | |
| Lilly USA, LLC | $305.81 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $201.98 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $185.67 | 2021-2025 | Repatha, Otezla, Otezla |
| Abbott Laboratories | $153.63 | 2021-2025 | Freestyle Libre 3 |
| Corcept Therapeutics | $134.31 | 2024-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.58 | 2024-2025 | Jardiance, Tradjenta |
| Exact Sciences Corporation | $128.31 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $112.06 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $96.26 | 2021-2024 | Xarelto |
| Astellas Pharma US INC | $95.54 | 2023-2025 | Veozah |
| Currax Pharmaceuticals LLC | $53.53 | 2021-2022 | |
| Radius Health, INC. | $44.56 | 2024-2025 | Tymlos |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $39.02 | 2022 | |
| Nestle Healthcare Nutrition INC. | $38.61 | 2021-2023 | |
| Pfizer INC. | $36.66 | 2025 | |
| Amarin Pharma, INC. | $30.74 | 2021 | |
| Daiichi Sankyo INC. | $19.36 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.39 | 2025 | Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.05 | 2024 | Xifaxan, Trulance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaili Gehring listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.